News
DRRX
1.340
+1.52%
0.020
Weekly Report: what happened at DRRX last week (1021-1025)?
Weekly Report · 5d ago
Weekly Report: what happened at DRRX last week (1014-1018)?
Weekly Report · 10/21 12:05
Weekly Report: what happened at DRRX last week (1007-1011)?
Weekly Report · 10/14 12:45
Weekly Report: what happened at DRRX last week (0930-1004)?
Weekly Report · 10/07 12:31
Weekly Report: what happened at DRRX last week (0923-0927)?
Weekly Report · 09/30 12:21
Analysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)
TipRanks · 09/29 08:10
Durect Corp Annual Meeting Decisions and Shareholder Votes
TipRanks · 09/26 21:00
Durect agreement on larsucosterol trial ‘a major positive,’ says Northland
TipRanks · 09/26 13:00
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 09/26 10:39
Durect (DRRX) Receives a Hold from H.C. Wainwright
TipRanks · 09/26 10:27
DURECT CORP - PHASE 3 TRIAL TO MEASURE 90-DAY SURVIVAL ENDPOINT
Reuters · 09/25 12:00
Weekly Report: what happened at DRRX last week (0916-0920)?
Weekly Report · 09/23 12:19
Weekly Report: what happened at DRRX last week (0909-0913)?
Weekly Report · 09/16 12:05
Weekly Report: what happened at DRRX last week (0902-0906)?
Weekly Report · 09/09 12:21
Weekly Report: what happened at DRRX last week (0826-0830)?
Weekly Report · 09/02 12:25
Weekly Report: what happened at DRRX last week (0819-0823)?
Weekly Report · 08/26 12:22
Weekly Report: what happened at DRRX last week (0812-0816)?
Weekly Report · 08/19 12:02
Based on the provided financial report, the title of the article is: "Form 10-Q: Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" This title indicates that the report is a quarterly report filed by Durect Corporation with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
Press release · 08/14 23:15
DURECT files for $250M mixed securities shelf
Seeking Alpha · 08/14 21:31
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
TipRanks · 08/14 10:40
More
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.